News

The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.
Federal health agencies including the NIH, FDA, and CDC laid off over 10,000 employees following a Supreme Court ruling.
Infant vaccination rates improved from 2023 to 2024, but millions of infants still do not receive routine vaccination.
Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.